Pharmafile Logo
Pharmafocus logo
Advanced Search

JAK inhibitor

Showing 3 posts of 3 posts found.

AbbVie posts promising data on RA drug

June 8, 2017
Research and Development AbbVie, JAK inhibitor

AbbVie posted results on upadacitinib, the latest drug in its pipeline for rheumatoid arthritis (RA) and the results have given …

News
pfizer-building-logo1web

Pfizer’s JAK inhibitor meets endpoints in Phase III ulcerative colitis trials

March 21, 2016
Research and Development, Sales and Marketing JAK inhibitor, Pfizer, ecco, endpoint, octave, tofacitinib, ulcerative colitis

Pfizer (NYSE:PFE) has announced that investigational JAK inhibitor – oral tofacitinib – met the primary and secondary endpoints in two …

News

Pfizer’s RA drug on course for approval

May 10, 2012
Sales and Marketing Humira, JAK inhibitor, Pfizer, RA, rheumatoid arthritis, tofacitinib

An FDA advisory committee has recommended for approval Pfizer’s new rheumatoid arthritis treatment tofacitinib.The Arthritis Advisory Committee voted 8-2 to …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025